Cheung Laboratories Inc., CLI, enters into an exclusive license agreement for innovative patented technology to be used for the treatment of prostate diseases.COLUMBIA, Md.--(BUSINESS WIRE)--Aug. 28, 1996--CLI (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CGLB) has entered into an exclusive license agreement for the commercialization rights to a patented technology for the treatment of symptomatic problems associated with prostatic diseases. This technology is expected to be used in conjunction with CLI's current line of prostatic microwave hyperthermia hyperthermia /hy·per·ther·mia/ (-ther´me-ah) hyperpyrexia; greatly increased body temperature.hyperther´malhyperther´mic malignant hyperthermia systems. The use of this technology is a viable treatment alternative to drugs and surgery for the millions of men who suffer from problems associated with enlarged prostates. The prostate is a walnut-sized gland which surrounds the urethra just below the bladder. Benign Prostatic Hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ) is a common condition afflicting more than 50% of all men over the age of 55. This patented technology is a bi-modal approach which combines heat with compression of the walls of the prostatic urethra to achieve better treatment results. CLI (1) (Call Level Interface) A database programming interface from the SQL Access Group (SAG), an SQL membership organization. SAG's CLI is an attempt to standardize the SQL language for database access. believes this will give our BPH systems a competitive advantage over existing systems. This bi-modal treatment can be administered on an out-patient basis. CLI further believes this patented technology has the potential to shorten the treatment time and lower the treatment temperature, thus resulting in a safer and more patient-friendly BPH treatment. Preclinical evaluation results using this new technology are very encouraging. On May 7, 1996, the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for the first time, approved a microwave-based BPH treatment device manufactured by EDAP EDAP Eating Disorders Awareness and Prevention EDAP Extended Data Availability and Protection (fault tolerant disk technology) EDAP Emergency Department Approved for Pediatrics EDAP Energy Descent Action Plan Technomed Inc. This approval should enhance market acceptance of microwave BPH treatment systems both in the USA and abroad. Currently, CLI manufactures and sells its BPH treatment systems outside the USA through its Canadian facility. CLI's BPH systems are not approved by the FDA for USA sales. However, CLI intends in the near future to apply for FDA approval. CLI has its main office in Columbia, is traded on the OTC market (symbol CGLB), and has offices in Toronto, and Hong Kong. A technology leader in the application of microwave technology, CLI designs, manufactures and sells hyperthermia medical equipment used for the treatment of cancer and prostatic diseases. CONTACT: Cheung Laboratories Inc., Columbia John Mon, 410/290-5390 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion